Stem cell transplant

Hematopoietic stem cells in bone marrow.
#Drug discovery #Hematopoietic stem cells #In vitro #Non-animal model (NAM) #Stem cell transplant #University of Glasgow

New bone marrow model ‘big news’ for drug discovery

Scientists have created the first bioengineered bone marrow model which can support the type of human stem cells that are crucial for bone marrow transplants and in vitro study work. The research – published in Nature Communications and led by the University of… Read More

#Editor's Choice #News

Bacteriophage
#Bacteriophage #Graft vs Host Disease #Japan #Phage therapy #Stem cell transplant

Bacteriophage study offers new hope in treating GVHD

Researchers from Japan have identified a bacteriophage-derived enzyme that holds promise for future applications in preventing or treating acute graft-versus-host disease (aGVHD). Acute GVHD is a medical condition that occurs when donor immune cells attack the recipient’s tissues after an allogeneic hematopoietic stem cell transplantation (allo-HCT). Read More

#News

#2024 predictions #Stem cell transplant #Stem cells #Therapeutics

2024 predictions: Experts weigh in on stem cells  

DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on the future of stem cells in drug discovery.   Melissa Little, CEO of the Novo Nordisk Foundation Centre for Stem Cell Medicine  “In the stem cell space, 2023 has seen significant increases in the delivery… Read More

#Exclusive Content

Diabetes patient injecting insulin
#allogeneic cell therapies #Cell therapy #Sana Biotechnology #Stem cell transplant #Type 1 diabetes

Insulin independence without immunosuppression

Preclinical data has demonstrated insulin independence following transplantation of hypoimmune (HIP) allogeneic primary islet cells without immunosuppression in a diabetic non-human primate (NHP). The study results were published in Cell Stem Cell, in a paper titled ‘Hypoimmune islets achieve insulin independence after allogeneic transplantation in a… Read More

#Editor's Choice #News

#Covid-19 #Immune system #Immunity #Immunology / Virology & Vaccines #Influenza #Stem cell transplant #TB vaccine

New DDW Highlights podcast: 22 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  With seasonal illnesses running amok in the western hemisphere at the moment, it is… Read More

#News

#Covid-19 #Immune system #Immunity #Immunology / Virology & Vaccines #Influenza #Stem cell transplant #TB vaccine

This week in drug discovery (15-19 January) 

News round-up for 15-19 January by DDW Digital Content Editor Diana Spencer. With seasonal illnesses running amok in the western hemisphere at the moment, it is perhaps not surprising that this week’s news highlights focus on viruses and immunity. The top stories: Antibody… Read More

#News

Stem cell transplant
#Cell therapy #Pluripotent stem cells #Regenerative Medicine #Stem cell transplant #Stem cells #University of Arizona

Genetically modified stem cells evade immune rejection

New research has brought stem cell transplantation without immune suppression closer to reality. Researchers at the University of Arizona Health Sciences say they are one step closer to understanding immunological rejection, a barrier to regenerative medicine, after genetically modifying pluripotent stem cells to evade immune recognition. Read More

#Editor's Choice #News

Stem cell transplant
#China #Cytomegalovirus #Phase III trial #Stem cell transplant #Takeda #Transplant

China’s NMPA okays maribavir for post-transplant cytomegalovirus

Takeda’s Livtencity (maribavir) has been approved in China for the treatment of adult patients with post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) cytomegalovirus (CMV) infection/disease. It has been licensed by the National Medical Products Administration (NMPA) in cases where the infection is resistant to treatment with ganciclovir,… Read More

#News #Regulatory

Arsenic Trioxide
#Anti-inflammatory #Arsenic Trioxide #Autoimmune disease #Graft vs Host Disease #Phase II trial #Stem cell transplant #Transplant

Phase II success for autoimmune disease platform in GVHD

BioSenic’s arsenic trioxide (ATO) autoimmune disease platform has completed a successful Phase IIb trial in chronic Graft vs Host Disease (cGVHD) and is preparing to move to a Phase III trial.  The BioSenic autoimmune platform was created by Medsenic to target systemic autoimmune diseases using ATO as… Read More

#News